Pharmaceutical

Eleven and Novo Nordisk partner to develop nucleic acid therapeutics

The companies will develop new molecules using Eleven's innovative DELiveri platform to treat cardiometabolic diseases.

Jul 17, 2023 - 20:00
Eleven and Novo Nordisk partner to develop nucleic acid therapeutics
The companies will develop new molecules using Eleven's innovative DELiveri platform to treat cardiometabolic diseases.
Read the original article

Tags:

Previous Article

FDA expands Veklury’s use to Covid-19 patients with severe kidney disease

Next Article

SNIPR celebrates US court’s favourable ruling on CRISPR patent

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more

STAT+: Pharmalittle: We are reading about Catalent conc...

Feb 9, 2024

Kidney doctors push to protect patients by including dialysis machines in emergency stockpile

Kidney doctors push to protect patients by including di...

Aug 7, 2023

ESCMID 2024: Drug resistance in fungi – a growing issue

ESCMID 2024: Drug resistance in fungi – a growing issue

May 3, 2024